Published date: 13 December 2019
Last edited date: 15 January 2021
Closed future opportunity - This means that a potential contract has passed its approach to market date. A buyer can choose to consider any supplier interest or convert this notice into an opportunity ready for live procurement.
Contract summary
Industry
Immunoglobulins - 33651520
Location of contract
England, Scotland, Northern Ireland, Isle of Man, Channel Islands
Value of contract
£450,000,000
Procurement reference
CM/PHS/17/5550
Published date
13 December 2019
Approach to market date
21 January 2021
Contract start date
1 July 2021
Contract end date
31 December 2022
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
Human Normal Immunoglobulin and Anti-D Immunoglobulin:
Period of framework agreement: 1 July 2021 to 31 December 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
More information
Spend profile
| Financial year | Budget |
|---|---|
| 2021/2022 | £225,000,000 |
| 2022/2023 | £225,000,000 |
About the buyer
Contact name
Darryn Boardman
Address
Commercial Medicines Unit
2nd Floor, Rutland House
Runcorn
WA7 2ES
England
Share this notice
Approach to market date: 21 January 2021
All content is available under the
